Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]

Investment Rating - The report does not provide a specific investment rating for the industry or companies mentioned [1]. Core Insights - The report highlights several new stock listings and trading activities scheduled for November 18, 2025, including companies such as Jingchuang Electric (12.10), Beikang Testing (6.70), and Nanguang Digital (5.69) [1]. - It also mentions various corporate actions such as tender offers, cash options, and acquisition requests, indicating active market movements [1]. Summary by Relevant Sections - **New Stock Listings**: Companies like Jingchuang Electric, Beikang Testing, and Nanguang Digital are set to debut on the market with respective prices of 12.10, 6.70, and 5.69 [1]. - **Corporate Actions**: The report details several corporate actions including a tender offer for Tianpu Co. (605255) from November 20 to December 19, 2025, and cash options for Hangqi Wheel B (200771) from November 19 to November 25, 2025 [1]. - **Market Alerts**: It lists companies experiencing significant fluctuations, such as Moen Electric (002451) and Huasheng Lithium Battery (688353), indicating potential investment risks and opportunities [1].

Market Overview - The Chinese medicine sector experienced a decline of 1.1% on November 18, with Te Yi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Te Yi Pharmaceutical (002728) saw a significant drop of 10.02%, closing at 12.75 [2] - Other notable declines included Zhongsheng Pharmaceutical (002317) down 9.99% and Jiaying Pharmaceutical (002198) down 9.96% [2] - The trading volume for Te Yi Pharmaceutical was 978,300 shares, indicating high activity despite the price drop [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 1.771 billion yuan from institutional investors, while retail investors saw a net inflow of 1.701 billion yuan [2][3] - The data indicates that while institutional investors are pulling back, retail investors are actively buying into the sector [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 14.04 million yuan from institutional investors, while it faced a net outflow of 21.57 million yuan from speculative funds [3] - Lingrui Pharmaceutical (600285) also saw a net inflow of 9.86 million yuan from institutional investors, but faced outflows from both speculative and retail investors [3]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 嘉应制药(002198.SZ)公告称，公司股票交易价格连续两个交易日累计偏离22.47%，属于股票交易异常 波动情况。经核实，公司前期披露信息无更正或补充，近期经营正常，内外部环境无重大变化，无未公 开重大信息影响股价，公司无控股股东和实际控制人，不存在应披露而未披露的重大事项或筹划阶段的 重大事项。公司5%以上股东在股票异常波动期间未买卖公司股票。此外，公司因涉嫌信息披露违法违 规被证监会立案调查，目前尚未收到最终决定。 ...

本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动情况 广东嘉应制药股份有限公司（以下简称"公司"）股票（证券简称：嘉应制 药，证券代码：002198）交易价格连续2个交易日内（2025年11月14日、2025年 11月17日）收盘价格累计偏离22.47%。根据《深圳证券交易所股票交易规则》相 关规定，属于股票交易异常波动的情况。 证券代码：002198 证券简称：嘉应制药 公告编号：2025-061 广东嘉应制药股份有限公司 关于股票交易异常波动的公告 针对公司股票异常波动情况，根据相关规定的要求，公司对有关事项进行了 核查，并发函询问了公司5%以上机构股东东方证券股份有限公司、养天和大药 房股份有限公司，现就相关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、近期公司经营情况正常，内外部经营环境未发生重大变化； 3、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 4、公司目前无控股股东和实际控制人，公司不存在应披露而未披露的重大 事项，亦不存在处于筹划阶段的重大事项； 二 ...

Market Overview - The Chinese traditional medicine sector experienced a decline of 1.47% on November 17, with Wanbangde leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Jiaying Pharmaceutical (002198) with a closing price of 8.43, up 10.05% and a trading volume of 390,200 shares [1] - Weikang Pharmaceutical (300878) closed at 29.62, up 6.85% with a trading volume of 97,100 shares [1] - Significant losers included: - Wanbangde (002082) closed at 13.61, down 6.91% with a trading volume of 186,000 shares [2] - Teyi Pharmaceutical (002728) closed at 14.17, down 6.84% with a trading volume of 1,277,300 shares [2] Capital Flow - The traditional medicine sector saw a net outflow of 1.639 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.444 billion yuan [2][3] - The main stocks with significant capital inflow included: - Jiaying Pharmaceutical with a net inflow of 62.818 million yuan, accounting for 19.12% of its trading volume [3] - Huasheng Technology (000790) with a net inflow of 20.121 million yuan, representing 11.37% of its trading volume [3]

转自：证券时报 人民财讯11月17日电，嘉应制药(002198)11月17日发布股票交易异常波动的公告，近期公司经营情况正 常，内外部经营环境未发生重大变化，公司目前无控股股东和实际控制人，公司不存在应披露而未披露 的重大事项，亦不存在处于筹划阶段的重大事项。 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2025-061 二、公司关注并核实相关情况 针对公司股票异常波动情况，根据相关规定的要求，公司对有关事项进行了 核查，现就相关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、近期公司经营情况正常，内外部经营环境未发生重大变化； 3、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 广东嘉应制药股份有限公司 关于股票交易异常波动的公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动情况 广东嘉应制药股份有限公司（以下简称"公司"）股票（证券简称：嘉应制 药，证券代码：002198）交易价格连续3个交易日内（2025年11月13日、2025年 11月14日、2025年11月17日）收盘价格涨幅偏离值累计超过20%。根据《深圳证 券交易所股票交易规则》相关规定，属于股票交易异常波动的情况。 敬请广大投资者理性投资，注意风险。 特此公告。 广东嘉应制药股份有限公司董事会 4、公司目前无控股股东和实际控制人，公司不存在应披露而未 ...

嘉应制药公告，公司股票交易价格连续3个交易日内（2025年11月13日、2025年11月14日、2025年11月 17日）收盘价格涨幅偏离值累计超过20%。公司前期披露的信息不存在需要更正、补充之处；近期公司 经营情况正常，内外部经营环境未发生重大变化；公司未发现近期公共媒体报道了可能或已经对本公司 股票交易价格产生较大影响的未公开重大信息；公司目前无控股股东和实际控制人，公司不存在应披露 而未披露的重大事项，亦不存在处于筹划阶段的重大事项。 ...

一、买卖嘉应制药002198股票的对账单原件 （1）对账单原件需要加盖证券公司营业部印章； 登录新浪财经APP 搜索【信披】查看更多考评等级 2025年5月28日晚间，广东嘉应制药（维权）股份有限公司（证券简称：嘉应制药，证券代码： 002198）发布《关于收到中国证券监督管理委员会立案告知书的公告》。公告显示：公司于近日收到中 国证券监督管理委员会《立案告知书》。根据《立案告知书》，因涉嫌信息披露违法违规，根据《中华 人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定立案。 经查，嘉应制药涉嫌的违法违规事实主要包括：未及时披露关联交易及关联方非经营性资金占用。2024 年第四季度，公司与养天和大药房股份有限公司等发生多笔关联交易，涉及金额1039.94万元，未及时 履行审议程序和信息披露义务，直至2025年4月才进行补充披露。此外，2024年9月至2025年1月期间， 关联方湖南药聚能医药有限公司以"月初转出、月末转回"的方式非经营性占用嘉应制药资金，累计金额 达到约2.35亿元。 上海百悦律师事务所牛彬律师表示，嘉应制药遭证监会立案，投资者或可索赔。 初步索赔范围：2024-10-0 ...